Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TBAJ 876

Next Previous
Search
Drug Profile

TBAJ 876

Alternative Names: NC-009; TBAJ-876

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Global Alliance for TB Drug Development
  • Class Antituberculars; Dimethylamines; Ethers; Halogenated hydrocarbons; Naphthalenes; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis
  • No development reported Nontuberculous mycobacterium infections

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for preclinical development in Nontuberculous-mycobacterium-infections in USA (PO, Tablet)
  • 21 Nov 2023 Pharmacodynamics data from preclinical studies in Tuberculosis released by Global Alliance for TB Drug Development
  • 16 Nov 2023 Phase-II clinical trials in Tuberculosis (Combination therapy) in Uganda, Tanzania, South Africa, Philippines, Georgia (PO) (NCT06058299)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top